January 16, 2019
The Patented Medicine Prices Review Board will hold a public hearing in the matter of the price of the patented medicine cysteamine bitartrate, sold under the trade name “Procysbi” by the patentee Horizon Therapeutics Canada.
December 12, 2018
Spending on drug class grew by 16.7% in 2017 and stands at just under $700 million
December 5, 2018
Governor in Council selection processes underway
September 11, 2018
Increased spending on high cost drugs and reduced savings from generics responsible for 6.3% average growth over 2 years.
August 22, 2018
The Honourable Ginette Petitpas Taylor, Federal Minister of Health, today tabled the 2017 Annual Report of the Patented Medicine Prices Review Board (PMPRB) with the Clerks of the House of Commons and the Senate.